Solnatide
Also known as: AP301, Solnatide, TIP peptide, TNF-alpha-derived TIP peptide
Source Solnatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Solnatide (AP301) is a 17‑amino‑acid synthetic peptide derived from the lectin‑like domain of TNF‑α, under clinical investigation for treatment of acute lung injury, ARDS and pulmonary edema via ENaC activation.
Mechanism of Action
Mimics the lectin‑like domain of TNF‑α, binds to and activates epithelial sodium channels (ENaC) in alveolar epithelium, enhancing Na⁺/fluid reabsorption and promoting alveolar fluid clearance
Routes of Administration
Goals & Uses
- Anti-inflammatory effects in lungImmunomodulationLow
- Pulmonary EdemaCardiopulmonaryModerate
- Alveolar fluid clearance in ARDSPulmonary/critical CareModerate
- Acute Lung InjuryRespiratoryModerate
- Acute respiratory distress syndromePulmonaryModerate
- Treatment of pulmonary edemaPulmonary/critical CareModerate
- Reduction of ventilator-associated conditionsPulmonary/critical CareLow
Contraindications
- Severe chronic obstructive pulmonary disease with active bronchospasmRespiratoryModerate
- Known hypersensitivity to Solnatide or any excipientsAllergyHigh
- Hypersensitivity to solnatide or excipientsAllergy/hypersensitivityHigh
- Severe airway obstruction incompatible with inhalationPulmonaryModerate
Adverse Effects
- Hypersensitivity reactionsImmunologicRare
- Local airway irritationRespiratoryCommon
- CoughRespiratoryCommonPersistent or episodic cough
- BronchospasmRespiratoryUncommon
- Throat irritationLocal / RespiratoryCommon
Drug Interactions
- DiureticsLowMay worsen dehydration or electrolyte imbalance
- Bronchodilators (e.g., albuterol)Low
- Inhaled corticosteroidsLow
Population Constraints
- Pediatric patientsAgeRelative
- Pediatric patients (<12 y)AgeRelative
- Severely immunocompromised patientsImmunologicalRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trials under EMA oversight
- United StatesInvestigationalIND holder; Phase II trial ongoing
- United KingdomInvestigationalTrial sponsor holds Clinical Trial Authorisation
Completed Phase I trials; Phase II trials ongoing in the EU and US for ARDS and cardiogenic pulmonary edema. Not approved for any indication.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Solnatide?
Solnatide (AP301) is a 17‑amino‑acid synthetic peptide derived from the lectin‑like domain of TNF‑α, under clinical investigation for treatment of acute lung injury, ARDS and pulmonary edema via ENaC activation.
What is Solnatide used for?
Solnatide is educationally associated with: Anti-inflammatory effects in lung, Pulmonary Edema, Alveolar fluid clearance in ARDS, Acute Lung Injury, Acute respiratory distress syndrome, Treatment of pulmonary edema, Reduction of ventilator-associated conditions. Educational only — not medical advice.
How is Solnatide administered?
Recorded routes of administration: Inhalation.
What are the potential side effects of Solnatide?
Reported adverse effects include: Hypersensitivity reactions, Local airway irritation, Cough, Bronchospasm, Throat irritation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Solnatide?
Recorded contraindications: Severe chronic obstructive pulmonary disease with active bronchospasm, Known hypersensitivity to Solnatide or any excipients, Hypersensitivity to solnatide or excipients, Severe airway obstruction incompatible with inhalation. Consult a qualified clinician before use.